Magdalena Harrington is a subject matter expert in clinical outcomes assessment (COA) research with over 15 years of experience in delivering health outcomes strategies that demonstrate clinical and economic value of new medicines. She joined Pfizer in 2018 and is leading Patient-Centered Outcomes Assessment (PCOA) team of COA scientists, designing and implementing COA strategies for successful registration and access across the enterprise.
Before joining Pfizer, Magdalena developed and implemented patient-centered COA strategies at Shire (now Takeda). Magdalena has extensive training in qualitative and quantitative instrument development methods.
Before joining pharmaceutical field, Magdalena developed health outcome measures in academia at The Warren Alpert Medical School of Brown University and University of Rhode Island. She also worked on innovative approaches to collecting patient experience data and developing patient-centered measures using online patient communities at PatientsLikeMe. She holds PhD in Quantitative Psychology form University of Rhode Island and Master of Arts in Clinical Psychology from University of Wroclaw in Poland. She lives in New Hampshire. Magdalena is passionate about ensuring robust patient input and consideration within regulatory and payer decision making.
